Browse by Poster Presenter

Skip to main content

ACoP 2024 Main banner

Conference Program

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

J
Jadhav, Satyawan

Alnylam Pharmaceuticals
(M-049) Disease Progression Modeling of Stargardt’s disease
Satyawan Jadhav
Favorite
Jarugula, Praneeth

Bristol Myers Squibb
(W-050) Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analysis of Danicamtiv in Heart Failure with Reduced Ejection Fraction
Praneeth Jarugula
Favorite
Javidi, Mehrdad
(M-004) MBMA Bridging Models as A Tool for Exploration of Clinical Endpoints in Unstudied Indications.
Mehrdad Javidi
Favorite
Jayachandran, Priya

Regeneron Pharmaceuticals, Inc.
(W-051) Model-based ‘learn and confirm approach’ demonstrates similarity of cemiplimab exposure in pediatric and adult populations
Priya Jayachandran
Favorite
Jeon, Jihyun

Chungnam National University
(T-058) Exposure-response (E-R) relationship between PD-L1 recombinant monoclonal antibody IMC-001 in relapsed or refractory extranodal NK/T cell lymphoma nasal type patients
Jihyun Jeon
Favorite
Jeon, Jiyeon

Chungnam National University
(T-059) Population Pharmacokinetic Approach to Evaluate Current Recommended Dose of Tacrolimus on Korean Pediatric Liver Transplant Patients
Jiyeon Jeon
Favorite
Jiang, Weihua

School of Pharmacy and Pharmaceutical Sciences, University at Buffalo
(W-052) Hybrid Minimal Physiological-Based Pharmacokinetic Model of Tenofovir Alafenamide and Its Metabolites Disposition in Humans
Weihua Jiang
Favorite
Job, Kathleen

The University of Utah
(W-054) Effects of sparse sampling in the characterization of leuprolide pharmacokinetics and pharmacodynamics in patients with prostate cancer
Kathleen Job
Favorite
Johnson, Carter

Certara
(T-061) Impact of PD-L2 on Relative Efficacy of Anti-PD-1 and Anti-PD-L1 Antibodies: Insights From QSP-Based Meta-Analysis
Carter Johnson
Favorite
Johnson, Jordon

Arcus Biosciences Inc.
(W-055) Confounding Impact of Event-Driven Exposure Phenomenon on Summary Exposure Metrics in Time-to-Event Exposure Response Analyses
Jordon Johnson
Favorite
(W-056) Population Pharmacokinetics of Quemliclustat, a Potent, Selective, and Reversible CD73 Inhibitor, in Patients with Cancer
Jordon Johnson
Favorite
Jomphe, Claudia

Certara
(M-037) K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Claudia Jomphe
Favorite
Jones, Hannah

Certara, Simcyp Consultancy Division
(W-124) Real world examples of PBPK impact on CYP3A4 victim DDI drug label content
Hannah Jones
Favorite
Jonsson, E. Niclas

Pharmetheus AB
(M-051) The impact of misspecified covariate models on inclusion and omission bias when using FREM and FFEM
E. Niclas Jonsson
Favorite
Jonsson, Fredrik

qPharmetra LLC
(M-050) Exposure-Response Analysis of Cenobamate
Fredrik Jonsson
Favorite
Jo, Seongjun

The State University of New York at Buffalo
(W-053) Development of physiologically based pharmacokinetic models for RET inhibitors to predict brain distribution
Seongjun Jo
Favorite
Joslyn, Louis

Preclinical and Translational Pharmacokinetics/Pharmacodynamics, Genentech
(T-062) A Pharmacologically-informed Neural Ordinary Differential Equation Framework to Predict Preclinical Pharmacokinetics
Louis Joslyn
Favorite